Billiontoone (NASDAQ:BLLN) Releases Quarterly Earnings Results, Beats Expectations By $0.33 EPS

Billiontoone (NASDAQ:BLLN) announced its earnings results on Wednesday. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.01 by $0.33, Zacks reports. The business had revenue of $108.39 million during the quarter, compared to analyst estimates of $95.81 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The firm’s revenue was up 83.8% compared to the same quarter last year.

Here are the key takeaways from Billiontoone’s conference call:

• Q1 financials were strong — revenue grew 84% YoY to $108.4M with 44% test volume growth, a 73% gross margin, 16% GAAP operating margin, and $537M cash, delivering profitability and positive cash flow.
• Market access and pricing momentum — BillionToOne is now in‑network with Anthem and UnitedHealthcare, reaching ~300 million contracted lives, and ASPs rose 28% YoY to $571, prompting raised 2026 revenue guidance to $450–$465M.
• Product differentiation — the launch of Unity Confirm, the company’s non‑invasive fetal cell–based confirmation assay, showed initial 100% concordance versus invasive diagnostics and is positioned to strengthen Unity as a frontline prenatal offering.
• Oncology ramp shows momentum (oncology revenue nearly 5x to $10.7M and tumor‑naive MRD on track), but longer‑term upside depends on achieving Medicare coverage for Northstar Response and scaling to improve oncology margins.
• Near‑term limits and risks — BillionToOne expects Unity Confirm to address only ~0.5–1% of patients (so minimal direct revenue), its prospective concordance study may take 1–3 years, and accounts receivable rose due to new payer contracts, which could affect short‑term cash conversion.

Billiontoone Stock Performance

BLLN traded down $4.69 during midday trading on Friday, reaching $88.22. 611,227 shares of the company were exchanged, compared to its average volume of 345,767. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12. The firm has a market cap of $4.05 billion and a PE ratio of 423.36. The company’s 50-day simple moving average is $77.96. Billiontoone has a one year low of $61.96 and a one year high of $138.70.

Hedge Funds Weigh In On Billiontoone

Hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new stake in Billiontoone during the 4th quarter worth $39,717,000. JPMorgan Chase & Co. acquired a new position in shares of Billiontoone in the 4th quarter valued at approximately $32,078,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Billiontoone in the 4th quarter valued at $18,631,000. Invesco Ltd. acquired a new position in shares of Billiontoone during the fourth quarter worth about $15,535,000. Finally, Bamco Inc. NY acquired a new stake in Billiontoone in the 4th quarter valued at approximately $13,913,000.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Billiontoone in a report on Friday, May 1st. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Wells Fargo & Company lowered their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research decreased their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday. Finally, JPMorgan Chase & Co. upped their target price on shares of Billiontoone from $120.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $122.43.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.